These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 31802108)
21. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565 [TBL] [Abstract][Full Text] [Related]
22. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment]. Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512 [TBL] [Abstract][Full Text] [Related]
24. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434 [TBL] [Abstract][Full Text] [Related]
25. Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer. Berenguer Frances MA; Linares-Galiana I; Cañas Cortés R; Marín I Borrás S; Gutiérrez Miguélez C; Najjari D; Slocker A; Bellobí C; Santacana M; Pané Foix M; Alonso MH; Navarro-Martin A; Comas Antón S; Guedea F Brachytherapy; 2020; 19(1):51-59. PubMed ID: 31690516 [TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population. Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664 [TBL] [Abstract][Full Text] [Related]
28. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4 Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422 [TBL] [Abstract][Full Text] [Related]
29. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma. Liu P; Xiao Q; Zhou B; Dai Z; Kang Y World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313 [TBL] [Abstract][Full Text] [Related]
30. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients. Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066 [TBL] [Abstract][Full Text] [Related]
31. TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis. Melotti S; Ambrosi F; Franceschini T; Giunchi F; Filippo GD; Franchini E; Massari F; Mollica V; Tateo V; Bianchi FM; Colecchia M; Acosta AM; Lobo J; Fiorentino M; Ricci C Pathol Res Pract; 2023 Jul; 247():154540. PubMed ID: 37209574 [TBL] [Abstract][Full Text] [Related]
32. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101 [TBL] [Abstract][Full Text] [Related]
33. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer. Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023 [TBL] [Abstract][Full Text] [Related]
34. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250 [TBL] [Abstract][Full Text] [Related]
35. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989 [TBL] [Abstract][Full Text] [Related]
36. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525 [TBL] [Abstract][Full Text] [Related]
37. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. Dix Junqueira Pinto G; de Souza Viana L; Scapulatempo Neto C; Vicente Serrano S J Immunol Res; 2016; 2016():9839685. PubMed ID: 27747247 [TBL] [Abstract][Full Text] [Related]
39. N-cadherin expression in primary and metastatic testicular germ cell tumors. Aytac Vuruskan B; Ozturk Nazlioglu H; Vuruskan H J BUON; 2018; 23(4):1125-1129. PubMed ID: 30358221 [TBL] [Abstract][Full Text] [Related]
40. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Tsuda S; Carreras J; Kikuti YY; Nakae H; Dekiden-Monma M; Imai J; Tsuruya K; Nakamura J; Tsukune Y; Uchida T; Matsushima M; Roncador G; Suzuki T; Nakamura N; Mine T Pathol Int; 2019 May; 69(5):260-271. PubMed ID: 30990953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]